|Venture Round, 3/2010 |
|Partial Close, 10/2010 ||$1.9M|
|Series A, 3/2011 ||$2.85M|
|Series B, 7/2013 ||$3.14M|
|Debt, 9/2013 ||$2.53M|
Thermalin Diabetes, Incorporated develops a portfolio of insulin analogs to address both the fast-acting and long-acting insulin markets. The company was incorporated in 2007 and is based in Cleveland, Ohio.